New York, New York-- (Newsfile Corp. - February 7, 2025) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX) a California-based biopharmaceutical company, Tuesday announced the appointment of Naji Gehchan as Chief Medical and Development Officer. Gehchan will ...

EMERYVILLE, Calif. - Kyverna Therapeutics Inc. (NASDAQ: KYTX), a clinical-stage biopharmaceutical company with a market capitalization of $144 million, today announced the appointment of Dr. Naji ...

In connection with the appointment of Dr. Gehchan as Kyverna's Chief Medical and Development Officer, on January 22, 2025, Kyverna will grant Dr. Gehchan an option to purchase 425,000 shares of ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

EMERYVILLE, Calif. - Kyverna Therapeutics Inc. (NASDAQ: KYTX), a clinical-stage biopharmaceutical company with a market capitalization of $144 million, today announced the appointment of Dr. Naji ...

Kyverna Therapeutics logo (PRNewsfoto/Kyverna Therapeutics) "We are thrilled to welcome Naji, a seasoned clinical development leader skilled in immunology, to our team as we prepare for our next phase ...